{"groups":[{"description":"Participants were enrolled, assigned to Arm/Cohort = 1/Peritoneal Carcinomatosis Arm = 1/Intraperitoneal (IP) Catheter Placement and Bidirectional Chemotherapy Dose Level = DL 1 intravenous (IV) Paclitaxel Cycle 1 Day 2 (C1D2) 60mg/m\\^2 then 80mg/m\\^2 DL 1 intraperitoneal (IP) Paclitaxel Cycles 1-3 60mg/m\\^2 then Cycles 4-6 80mg/m\\^2 DL 1 by mouth (PO) Nilotinib 300mg twice a day (BID). Participants enrolled, assigned to an Arm/Cohort, and start protocol treatment.","id":"FG000","title":"Participants Enrolled, Assigned to Cohort 1/Arm 1 Peritoneal Carcinomatosis, and Treated"},{"description":"Participants were enrolled, assigned to Arm/(Cohort = 1/Peritoneal Carcinomatosis Arm = 1/Intraperitoneal (IP) Catheter Placement and Bidirectional Chemotherapy Dose Level = DL 1 intravenous (IV) Paclitaxel Cycle 1 Day 2 (C1D2) 60mg/m\\^2 then 80mg/m\\^2 DL 1 intraperitoneal (IP) Paclitaxel Cycles 1-3 60mg/m\\^2 then Cycles 4-6 80mg/m\\^2 DL 1 by mouth (PO) Nilotinib 300mg twice a day (BID)); but opted to come off-study prior to start of protocol treatment.","id":"FG001","title":"Participants Enrolled, Assigned to an Arm/Cohort, But Not Treated"},{"description":"Participants were enrolled, were not assigned to an Arm/Cohort and were not treated.","id":"FG002","title":"Participants Enrolled, Not Assigned to an Arm/Cohort and Not Treated"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Refused further treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Stopped treatment before completing 6 cycles of therapy due to clinical progression of disease."},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"8"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}],"type":"Screen failure"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Participant refused"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"12"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"De-escalated Nilotinib Dose"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"De-escalated Intravenous (IV) Paclitaxel Dose"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"De-escalated Intraperitoneal (IP) Paclitaxel Dose"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"12"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}